Bioxodes has shared promising interim results from the BIRCH Phase IIa clinical trial of its lead asset, BIOX-101, to treat intracerebral haemorrhagic stroke (ICH). 

Interim analysis from the first 16 patients in the trial showed that primary safety and secondary efficacy endpoints were met.  

“While preliminary, the data from this study all point in the right direction. This excellent result has given us the confidence to start the Phase IIb trial as soon as possible,” said Hans Warrinnier, Chief Medical Officer at Bioxodes. “Although haemorrhagic stroke often has debilitating consequences, it is a neglected disease, and the prospect of offering these patients hope is a strong motivating factor for our team.” 

No deaths have so far been recorded in the patient population, which the company says is a surprisingly positive outcome, and no serious adverse events were attributed to treatment over the course of the trial.  

Imaging data suggested a favourable evolution of hematoma and oedema volumes, while exploratory outcomes on inflammation biomarkers measurements were very encouraging. 

Bioxodes received Orphan Drug Designation for BIOX-101 in both the US and Europe in March 2025. The company is planning to file for PRIME status with the EMA and for Fast Track designation with the FDA. 

BIOX-101 is a recombinant version of a small protein found in the saliva of the tick (Ixodes ricinus). It is designed to inhibit the harmful secondary effects of haemorrhagic stroke such as secondary ischaemia, neuroinflammation and neuronal damage.  

The product exerts its anti-inflammatory effects by inhibiting activation of neutrophils and their release of extracellular DNA filaments (called NETs), which can cause excessive inflammation, exacerbating brain damage and disrupting the blood-brain barrier.  

BIOX-101 reduces clotting without increasing bleeding, by targeting Factors XIa and XIIa of the intrinsic coagulation pathway.  

Diana Spencer, Senior Digital Content Editor, DDW